Tumores hepáticos primarios malignos no hepatocarcinoma ni colangiocarcinoma / Primary malignant hepatic tumors other than hepatocarcinoma or cholangiocarcinoma: a series of cases

Background: There are several types of primary malignant hepatic tumors (PMHT) other than hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC): they are infrequent and poorly known. Imaging studies could help characterize the lesions and may guide the diagnosis. However, the definitive diagnosis of PMHT is made by pathology. Aim: To review a registry of liver biopsies performed to diagnose hepatic tumors. Patients and Methods: Review of a pathology registry of liver biopsies performed for the diagnosis of liver tumors. Among these, 25 patients aged 57 ± 17 years, 60% males, in whom a liver tumor other than a HCC or CC was diagnosed, were selected for review. The medical records of these patients were reviewed to register their clinical characteristics, imaging and the pathological diagnosis performed during surgery and/ or with the percutaneous liver biopsy. Results: Ten patients (40%) had neuroendocrine tumors, six (24%) had a lymphoma and four (16%) had hepatic hemangioendothelioma. Angiosarcoma and sarcomatoid carcinoma were diagnosed in one patient each. In 22 patients (88%), neither clinical features nor imaging studies gave the correct diagnosis. Four patients (16%) had chronic liver disease. The most frequent symptoms were weight loss in 28% and abdominal pain in 24%. Conclusions: The most common PMHT other than HCC and CC were neuroendocrine tumors and lymphomas. Imaging or clinical features were not helpful to reach the correct diagnosis.

Unknown primary large-cell neuroendocrine tumor

Large-cell neuroendocrine tumors (NETs) are poorly differentiated malignancies of rare incidence and aggressive nature. NETs mostly arise in the lung followed by the gastrointestinal tract, although they are potentially ubiquitous throughout the body. Primary unknown NET has a worse prognosis and shorter survival comparing with other NETs, with limited available data in the literature concerning this subgroup. The authors report the case of large-cell NET with supraclavicular lymph node presentation. Total excisional biopsy revealed an enlarged adenopathy 18 × 15 × 10 mm, which was extensively infiltrated by a solid malignant neoplasm composed of large cells with granular chromatin, nuclear pseudo-inclusions, high mitotic index, and focal necrosis, with a Ki 67 index 25-30% and positive immunohistochemical study for the expression of cytokeratin 8/18, chromogranin, synaptophysin, and thyroid transcriptional factor-1 (TTF-1). There was no evidence of primary location apart from two infracentimetric lung lesions that could not be accessed for biopsy and were negative at both somatostatin receptor scintigraphy and positron emission tomography. The NET relapsed with three mediastinal masses, so the patient was started on chemotherapy with carboplatin and etoposide with initial total response. Early progression showed no response to further chemotherapy regimens (temozolomide, oral etoposide); therefore, the patient was treated with local radiotherapy. This patient has an atypical long survival (54 months) compared to the literature data. In fact, there are few long-term survivors of large-cell NET and they are all related to complete surgical resection.

MRI findings and pathological features of occult breast cancer / 中华肿瘤杂志

Objective@#To investigate the magnetic resonance imaging (MRI) findings and clinicopathological features of primary lesions in patients with occult breast cancer (OBC).@*Methods@#The imaging reports from the Breast Imaging Reporting and Data System in 2013 were retrospectively analyzed to investigate the morphology and the time signal intensity curve (TIC) of breast lesions in patients with OBC. The clinical and pathological characteristics of these patients were also included.@*Results@#A total of 34 patients were enrolled. Among these patients, 24 patients underwent modified radical mastectomy and 18 of them had primary breast carcinoma in pathological sections. MRI detected 17 cases of primary lesions, including six masse lesions with a diameter of 0.6-1.2 cm (average 0.9 cm), and 11 non-mass lesions with four linear distributions, three segmental distributions, three focal distributions, and one regions distribution. Five patients had TIC typeⅠprimary lesions, ten had TIC type Ⅱ primary lesions, and two had TIC type Ⅲ primary lesions. Among all 34 cases, 23 of them had complete results of immunohistochemistry: 11 estrogen receptor (ER) positive lesions (47.8%), tenprogesterone receptor (PR) positive lesions (43.5%), seven human epidermal growth factor receptor 2 (HER-2) positive lesions (30.4%), and 20high expression(>14%) of Ki-67 (87.0%). The proportion of type luminal A was 4.3%, type luminal B was 43.5%, triple negative breast cancer (TNBC) was 30.4%, and HER-2 over expression accounted for 21.7%.@*Conclusions@#The primary lesions of OBC usually manifested as small mass lesions, or focal, linear or segmental distribution of non-mass lesions. The positive rate of ER and PR was low, but the positive rate of HER-2 and the proliferation index of Ki-67 was high. Type luminal B is the most common molecular subtype.

Cutaneous metastases in a patient with no previous diagnosis of cancer: diagnostic challenge

Abstract: On rare occasions, skin lesions are the first local of metastatic manifestation of internal malignancies. In case of no previous diagnosis of these tumors, the approach of suspicious skin lesions becomes a challenge, especially in differentiating cutaneous metastases and adnexal primary neoplasms. Currently, besides epidemiologic, dermoscopic and histopathologic aspects, the evaluation also integrates immunohistochemical exams and cell markers such as p40 and p63, highly specific for skin metastases. This article describes the case of cutaneous metastases as the sole obvious sign of breast cancer in a previously asymptomatic woman. The diagnosis was made by the finding of neoplastic cells in the dermis and immunohistochemistry compatible with ductal carcinoma.

Value of immunohistochemistry for determining the primary site of adenocarcinoma cells in pleural effusion cell block / 肿瘤研究与临床

Objective To explore the clinical significance of immunohistochemistry (IHC) for determining the primary site of adenocarcinoma cells in pleural effusion cell block. Methods One hundred and eight cases of pleural effusion diagnosed as adenocarcinoma were collected by using liquid-based cytology from January 2013 to June 2016 in Yuncheng Central Hospital. Sediment cells were gathered through centrifuging and paraffin block was made, then 94 cases were selected for IHC detection. Results Among 94 cases of adenocarcinoma diagnosed by using liquid-based cytology, 92 cases were still diagnosed as adenocarcinoma by IHC, including 70 cases of lung source, 2 cases of breast, 6 cases of ovary, 8 cases of alimentary canal, 1 case of peritoneal serouspapillary carcinoma, and 5 cases of unknown source. The other 2 cases were diagnosed as mesothelial cells and mesothelial tumors respectively. Conclusion Pleural effusion cells block and multiple IHC can improve the tumor cell detection for the judgement of the benign and malignant tumor cells and differential diagnosis to find the primary site of tumors.

Ovarian carcinoma presenting as cutaneous nasal metastasis

Abstract Metastatic ovarian cancer uncommonly presents with skin metastasis. When present, skin metastases of ovarian cancer are usually localized in the vicinity of the primary tumor. We report a case of a 58-year-old woman with a rapid growing erythematous, well-defined nodule localized on the left nasal ala. A skin biopsy was performed and histopathological and immunohistochemical findings were compatible with a cutaneous metastasis of adenocarcinoma. A systematic investigation revealed a bilateral ovarian cystadenocarcinoma associated with visceral dissemination, likely associated with nose cutaneous metastasis. We report a very uncommon case because of the presentation of ovarian carcinoma as cutaneous metastasis. To our knowledge, this atypical localization on the nose has not been described yet in the literature.

Optimal Treatment Decision for Brain Metastases of Unknown Primary Origin: The Role and Timing of Radiosurgery

BACKGROUND: Up to 15% of all patients with brain metastases have no clearly detected primary site despite intensive evaluation, and this incidence has decreased with the use of improved imaging technology. Radiosurgery has been evaluated as one of the treatment modality for patients with limited brain metastases. In this study, we evaluated the effectiveness of radiosurgery for brain metastases from unknown primary tumors. METHODS: We retrospectively evaluated 540 patients who underwent gamma knife radiosurgery (GKRS) for brain metastases radiologically diagnosed between August 1992 and September 2007 in our institution. First, the brain metastases were grouped into metachronous, synchronous, and precocious presentations according to the timing of diagnosis of the brain metastases. Then, synchronous and precocious brain metastases were further grouped into 1) unknown primary; 2) delayed known primary; and 3) synchronous metastases according to the timing of diagnosis of the primary origin. We analyzed the survival time and time to new brain metastasis in each group. RESULTS: Of the 540 patients, 29 (5.4%) presented precocious or synchronous metastases (34 GKRS procedures for 174 lesions). The primary tumor was not found even after intensive and repeated systemic evaluation in 10 patients (unknown primary, 34.5%); found after 8 months in 3 patients (delayed known primary, 1.2%); and diagnosed at the same time as the brain metastases in 16 patients (synchronous metastasis, 55.2%). No statistically significant differences in survival time and time to new brain metastasis were found among the three groups. CONCLUSION: Identification of a primary tumor before GKRS did not affect the patient outcomes. If other possible differential diagnoses were completely excluded, early GKRS can be an effective treatment option for brain metastases from unknown primary tumor.

Cutaneous metastasis of unknown primary presenting as massive and invasive abdominal lesion: an elective approach

Abstract: We describe herein what is to our knowledge the first reported case of an invasive cutaneous metastasis with unknown primary, electively treated solely with electrochemotherapy. We describe a female patient with a large, invasive and painful lesion in her hypogastric region, extending up to the pubic area. The cutaneous biopsy and instrumental and laboratory analyses, all failed to reveal the primary site. A final diagnosis of cutaneous metastasis with unknown primary was made and treatment was performed with electrochemotherapy. Our case highlights the importance of interdisciplinary choices in clinical practice to cope with the lack of a primary site and to improve quality of life, since no standardized therapy exists for these classes of patients.

Cutaneous metastasis from gastrointestinal adenocarcinoma of unknown primary origin

AbstractCutaneous metastasis is a rare manifestation of visceral malignancies that indicates primarily advanced disease. Due to its low incidence and similarity to other cutaneous lesions, it is not uncommon to have a delayed diagnosis and a shortened prognosis. We describe the case of a patient who presented with a cutaneous nodule in the sternal region as a first sign of malignancy.

Diagnosis and treatment of carcinoma of unknown primary / 国际肿瘤学杂志

The primary focal area of carcinoma of unknown primary (CUP) can not be determined by clinical examination.It is difficult to find the primary site and its prognosis is poor.The traditional diagnostic approaches mainly include pathological examination,endoscopy,imaging technology and so on.However,positron emission tomography is the preferred approach.In recent years,gene expression profiling has become a new diagnostic approach to find the source of CUP.The detection rate by gene expression profiling is high,and the approach can accurately identify the primary site.The recommended therapies include classic platinum-or paclitaxel-based chemotherapy,radiotherapy or surgery,and site-directed therapy by gene expression profiling for patients with CUP improves their survival rate.

Epidemiologia e análise de sobrevida de pacientes com melanoma metastáticode sítio primário conhecido e desconhecido / Epidemiology and analysis of survival of patients with known and unknown primary melanoma site

Introdução: O melanoma é essencialmente cutâneo. Em alguns pacientes, não é possível determinar a localização do tumor primário. A incidência de melanoma com sítio primário desconhecido varia de 2 a 15%. Objetivos: Determinar se há diferença de sobrevida global entre os pacientes com melanoma primário conhecido comparado aos pacientes com melanoma primário desconhecido. Métodos: Foi realizada análise retrospectiva de pacientes com melanoma no banco de dados da Oncologia Cirúrgica e Cirurgia do Aparelho Digestivo (ONCAD) e identificados aqueles com sítio primário desconhecido e metástases para diferentes locais. Resultados: O principal local de metástases foi o linfonodo (50%) - inguinais (25%),axilares (16%) e periaórticos (8,3%). Metástases pulmonares foram encontradas em três pacientes (25%). Metástases para fígado, osso e pele foram observadas em um caso cada (8,3%). Conclusão: A evolução clínica dos pacientes metastáticos com melanoma de sítio primário desconhecido é melhor em relação aos pacientes metastáticos com lesão primária conhecida, quando os dois grupos estão no mesmo estádio. Dessa forma, o fator mais determinante do curso clínico e do prognóstico éa localização das metástases. A maioria dos pacientes que apresenta doença sistêmica ao diagnóstico perde a chance de cura, como muitos pacientes com cutâneo primário fino e doença regional ao diagnóstico.

Introduction: Melanoma is essentially cutaneous. In some patients, it is not possible to determine the location of the primary tumor. The incidence of melanoma of unknown primary site varies from 2 ? 15%. Objectives: To determine whether there is difference in overall survival between patients with known primary melanoma compared to patients with unknown primary melanoma. Methods: A retrospective analysis of patients with melanoma in the database of Surgical Oncology and Digestive Surgery (ONCAD) was performed and identified those with unknown primary site and metastases to different locations. Results: Lymph node was the main site of metastases (50%) - inguinal (25%), axillary (16%) and periaortic (8.3%). Pulmonary metastases were found in three patients ( 25%). Metastasis to the liver, bone and skin were observed in one case each (8.3%). Conclusions: The clinical course of patients with metastatic melanomaof unknown primary site is better than metastatic patients with known primary lesion, when both groups are on the same stage. Thus, the most relevant determining factor affecting clinical course and prognosis is the metastasis location. Most patients presenting systemic disease at diagnosis loses the chance of cure as many patients with thin primary cutaneous and regional disease at diagnosis.

Epidemiological and histopathological profile of cutaneous melanoma at a center in northeastern Brazil from 2000 to 2010 / Perfil epidemiologico e histopatologico do melanoma cutaneo em um centro do nordeste brasileiro de 2000 a 2010

BACKGROUND: While representing only 3-4% of malignant skin tumors, cutaneous melanoma is the most aggressive and lethal. Statistical knowledge about the biological behavior of this tumor is essential for guiding daily outpatient practice and aiding public health policies. OBJECTIVES: To analyze the profile of patients with cutaneous melanoma attending a pathology department in Teresina (state of Piauí) between 2000 and 2010. METHODS: Retrospective study of melanoma patients diagnosed between 2000 and 2010 in the São Marcos Hospital in the city of Teresina. The pathology laboratory reports were studied and all the statistical analyses performed using SPSS 19.0. RESULTS: A total of 25 in situ, 199 invasive and 89 metastatic melanomas of unknown primary site were observed. Histological types found were nodular (52.8%), superficial spreading melanoma (18.6%), acral (10.6%) and lentigo maligna (9.5%). In 144 (73.4%) cases the Breslow thickness was >1 mm. Metastasis was found in 28.6% of invasive melanomas and nodular melanoma, Clark IV/ V, Breslow > 1 mm, mitotic index > 6 and ulcerated lesions were more likely to metastasize. CONCLUSION: Most melanomas presented Breslow> 1mm. The main factors associated with metastasis were nodular type, Clark IV / V, Breslow> 1mm, mitotic index > 6 and ulcerated lesions. .

FUNDAMENTOS: Apesar de representar apenas 3-4% dos tumores malignos de pele, o melanoma cutâneo é o mais agressivo e letal deles. O conhecimento estatístico do comportamento biológico deste tumor em nosso meio ambiente é fundamental para orientar a prática ambulatorial diária e para auxiliar políticas de saúde pública. OBJETIVOS: Analisar o perfil de pacientes com melanoma cutâneo diagnosticados em serviço de referência em patologia em Teresina-Piauí no período de 2000 a 2010. MÉTODOS: Estudo retrospectivo de pacientes com melanoma diagnosticados entre 2000 e 2010 no Hospital São Marcos, Teresina-Piauí-Brasil. Estudou-se laudos histopatológicos e realizou-se análises estatísticas com o programa SPSS 19,0. RESULTADOS: Um total de 25 melanomas in situ, 199 invasivos e 89 metastáticos de sítio primário desconhecido foram observados. Tipos histológicos encontrados foram nodular (52,8%), melanoma extensivo superficial (18,6%), acral (10,6%) e lentigo maligno (9,5%). Em 144 (73,4%) casos o índice de Breslow foi >1 mm. Verificou-se metástases em 28,6% dos melanomas invasivos e melanoma nodular, Clark IV/V, Breslow >1 mm, índice mitótico ≥6 e lesões ulceradas estavam mais propensos a metástases. CONCLUSÃO: Melanomas com Breslow >1mm foram os casos predominantes. Principais fatores ...

Abdome agudo como manifestação inicial de melanoma metastático: relato de caso / Acute abdomen as initial manifestation of metastatic melanoma

The malignant melanoma is a relatively common neoplasia, with origin generally in the melanocytics cells in the skin, but with presentation of other possible primary lesions, being presented in this, a case witnessed of liver and mesentery metastases with unknown primary sites.

Detection of primary sites of unknown primary tumors using 18F-FDG PET-CT / 肿瘤研究与临床

Objective To determine the value of 18F-FDG PET-CT in detecting the primary origin of cancer of unknown primary (CUP).Methods A total of 48 patients (age range 41-82 years,mean age of 57±16 years, 20 females) were retrospectively selected. All patients were diagnosed as CUP and were examined by 18F-FDG PET-CT scan.The patients were divided into cervical lymph node metastasis group (28 cases) and extra-cervical lymph node metastasis group (20 cases) according to different metastasis site.Sensitivity of 18F-FDG PET-CT to detect primary tumor site was compared between these two groups.Results 18F-FDG PET-CT detected primary tumors in 32 of 48 patients (66.7 ％), the cervical lymph node metastasis tumors in 22 of 28 patients (78.6 ％), and extra-cervical lymph node metastasis tumors in 10 of 20 patients (50.0 ％).There was significant difference between cervical lymph node metastasis group and extra-cervical lymph node metastasis group (x2 =4.286,P ＜ 0.05).Conclusion 18F-FDG PET-CT has a high sensitivity to detect primary origin of CUP,especially for patients with cervical lymph node metastasis.

Occult breast cancer, report of 62 cases / 中华普通外科杂志

ObjectiveTo analyze the clinical features and prognostic factors of occult breast cancer. MethodsThe clinical features and prognostic factors of 62 occult breast cancer patients,who were treated in Tianjin Cancer Hospital from October 1997 to October 2011,were retrospectively analyzed.ResultsThe 3-year,5-year and 10-year overall survival rates of 62 cases were 87.4％,76.4％,73.2％ respectively,a median of 53 months.The 3-,5-,and 10-year overall survival rates of the patients with ＞4 positive lymph nodes are lower than that of patients with ≤4 nodes (77.8％,64.8％,38.9％ vs.90.7％,86.7％,86.7％,P =0.015 ) ;The 3-year and 5-year overall survival rates of patients with primary cancer found in removed breast tissue are lower than that in those primary tumor was not found (60.0％,40.0％,40.0％ vs.92.0％,83.6％,79.2％,P =0.023).The 3-year,5-year and 10-year overall survival rates in patients with recurrence and metastasis are lower than that of patients without (63.5％,28.6％,19.0％ vs.97.1％,97.1 ％,97.1％,P =0.000). ConclusionsThe prognosis of occult breast cancer is related with the number of positive lymph node,pathology,recurrence and metastasis.

Neuroendocrine Tumor of Unknown Primary Accompanied with Stomach Adenocarcinoma

A 67 year old male at a regular checkup underwent esophagogastroduodenoscopy. On performing esophagogastroduodenoscopy, a lesion about 1.2 cm depressed was noted at the gastric angle. The pathology of the biopsy specimen revealed a well-differentiated adenocarcinoma. On performing an abdominal computed tomography (CT) scan & positron emission tomography-computed tomography (PET-CT) scan, no definite evidence of gastric wall thickening or mass lesion was found. However, lymph node enlargement was found in the left gastric and prepancreatic spaces. This patient underwent laparoscopic assisted distal gastrectomy and D2 lymph node dissection. On final examination, it was found out that the tumor had invaded the mucosal layer. The lymph node was a metastasized large cell neuroendocrine carcinoma with an unknown primary site. The patient refused chemotherapy. He opted to undergo a close follow-up. At the postoperative month 27, he had a focal hypermetabolic lesion in the left lobe of the liver that suggested metastasis on PET-CT scan. He refused to undergo an operation. He underwent a radiofrequency ablation.

Clinical diagnosis of metastatic cancers of unknown primary site / 国际肿瘤学杂志

The management of patients with cancer of unknown primary site (CUP) is a notoriously medical problem. The outcome is bad in most patients. The clinical general characteristics, histopathology, im-aging features and endoscopies can provide some useful information, and the primary site can be detected in part of these patients, but most are not. With the application of molecular biology and positron emission tomography-computed tomography(PET-CT) technology, the detection rate of CUP has increased significantly.

Clinical analysis of 106 cases of brain metastatic carcinoma / 中国基层医药

Objective To investigate the clinical and CT characteristics of metastatic brain carcinoma and the differential diagnosis with other intracranial lesions and promote diagnostic level one step more,and to diminish misdiagnosis.Methods 106 cases metastatic brain tumor confirmed by CT and other methods in our hospital from 1990 to 2005 were retrospectively studied about clinical appearance and the relationship with anatomy and physiology,characteristics of CT and the main point of differential diagnosis.Results Metastatic brain carcinoma mainly could be devided to three following types based on clinical expressions,among them,apoplexic type dominated 46 cases(43.4%),epileptic type 26 cases(24.5%),brain tumor type 24 cases(21.6%),the clinical expressions correlated to anatomy and phyiology of lesion in each type,CT plain scan most appeared low density or equal density space occupying enhanced CT scan foci showed different degree stronger in lesion,and characteristic of perifocal edema.Conclusion The clinical appearance of brain metastatic carcinoma is various,easily misdiagnosed in early stage,looking for the primary tumor is the rather important diagnostic dependencies,enhanced CT scan is an important diagnostic method.